top of page

البريد الإلكتروني: bd@sidmexinovia.com

رقم الهاتف: +918866862020

Heading 4

Heading 4

Heading 4

Heading 4

Heading 4

Heading 4

Heading 4

Heading 4

Heading 4

Heading 4

Heading 4

Heading 4

الرئيسية >

Hosvilda M 50/500mg Tablet

Hosvilda M 50/500mg Tablet

Manufacturer/Marketed By : HOSPIMAX HEALTHCARE PVT LTD

$0.90 $0.73

Hosvilda M 50/500mg Tablet contains an active component called Metformin and Vildagliptin.  It is used for the management of type 2 diabetes mellitus, which is a chronic condition that affects...

Collapsible text is perfect for longer content like paragraphs and descriptions. It's a great way to give people more information while keeping your layout clean. Link your text to anything, including an external website or a different page. You can set your text box to expand and collapse when people click, so they can read more or less info.

METFORMIN,VILDAGLIPTIN

Active Pharmaceutical Ingredient

Hosvilda M 50/500mg Tablet

SKU HOSVILDA-M-50-500MG-TABLET
السعر الأصلي

‏0.90 US$

سعر البيع

‏0.73 US$

Hosvilda M 50/500mg Tablet contains an active component called Metformin and Vildagliptin.  It is used for the management of type 2 diabetes mellitus, which is a chronic condition that affects the way the body processes blood sugar (glucose). This medication can be used to help control high blood sugar levels.  It may be used to improve insulin sensitivity in patients who are resistant to the effects of insulin. This medication might be used to manage blood sugar levels in individuals with overweight and obesity-related metabolic disorders. It should not be used in patients with known hypersensitivity or allergy to Hosvilda M 50/500mg Tablet or any other inactive ingredients in the medication. It should not be used in patients with severe renal impairment (creatinine clearance below 30 mL/min), as the kidneys primarily excrete this medication, and their clearance is reduced in patients with impaired renal function. Patients with a history of ketoacidosis, diabetic ketoacidosis, or lactic acidosis should not use this medication. It is not recommended for patients with severe liver impairment. Conditions such as heart failure, respiratory failure, recent myocardial infarction, and shock, which can lead to tissue hypoxia, are contraindications for the use of this medication. In patients who will be receiving iodinated contrast agents for radiologic studies, the use of this medication should be temporarily discontinued before or at the time of the procedure and not restarted until at least 48 hours after, provided that renal function has been re-evaluated and found to be stable. Elderly patients may be more susceptible to the side effects of this medication, particularly those related to kidney function. Regular monitoring of kidney function is essential. Hosvilda M 50/500mg Tablet is not recommended for use in children.

Active Pharmaceutical Ingredient

METFORMIN,VILDAGLIPTIN

الاستخدامات

• Management of type 2 diabetes mellitus
• Control of hyperglycemia
• Improvement of insulin sensitivity
• Weight management

فوائد

Hosvilda M 50/500mg Tablet works by combining the mechanisms of its two active ingredients, Vildagliptin and Metformin, to manage type 2 diabetes mellitus. Vildagliptin functions by inhibiting the enzyme DPP-4, which increases active incretin hormone levels, stimulating insulin secretion and reducing glucagon release. Metformin reduces hepatic glucose production, enhances peripheral glucose uptake, and improves insulin sensitivity through AMPK activation. This combined action helps regulate blood sugar levels through complementary pathways.

تأثيرات جانبية

Hosvilda M 50/500mg Tablet causes some side effects like all medications, although not everyone will experience them.

الآثار الجانبية الأكثر شيوعًا

• Gastrointestinal disturbances
• Hypoglycemia
• Headache
• Dizziness
• Weakness or fatigue
• Metallic taste in the mouth

الآثار الجانبية الشائعة

• Lactic acidosis
• Severe allergic reactions

كيفية الاستخدام

Hosvilda M 50/500mg Tablet is administered orally as tablets. The recommended starting dosage and any necessary dose adjustments are determined based on the specific condition being treated and the patient's response to the medication.

نصائح السلامة

• Breast Feeding: It is not safe to use this medication during breastfeeding. It is advised to discontinue either the medication or breastfeeding, depending on the importance of the drug to the mother.
• Alcohol: It is advisable to avoid excessive alcohol consumption while taking  Hosvilda M 50/500mg Tablet, as it may increase the risk of lactic acidosis. Consult your healthcare provider regarding the consumption of alcohol while on this medication.
• Liver: If you have liver disorders, informing your healthcare provider before starting Hosvilda M 50/500mg Tablet is important.
• Lungs: Consult your healthcare provider if you have a history of lung conditions before using  Hosvilda M 50/500mg Tablet.
• Driving: Hosvilda M 50/500mg Tablet may cause dizziness or drowsiness in some patients. If you experience these symptoms, consult your healthcare provider if you experience side effe
• Pregnancy: It is advisable to consult your healthcare provider before taking Hosvilda M 50/500mg Tablet, as it is not recommended during pregnancy

تنصل

تسعى شركة Sidmex Inovia جاهدة لتوفير معلومات دقيقة وموثوقة؛ ومع ذلك، فإن جميع المحتويات الموجودة على هذا الموقع الإلكتروني، بما في ذلك أوصاف المنتجات ومكوناتها، هي لأغراض إعلامية فقط ولا ينبغي اعتبارها بديلاً عن المشورة الطبية المهنية أو التشخيص أو العلاج.

يُنصح المستخدمون باستشارة أخصائي رعاية صحية مؤهل قبل اتخاذ أي قرارات طبية. لا ينبغي استخدام المعلومات المقدمة للتشخيص الذاتي أو العلاج الذاتي.

جميع المنتجات المذكورة مخصصة حصراً لأغراض التعاملات التجارية بين الشركات والاستفسارات بالجملة. لا تشجع شركة سيدمكس إينوفيا الاستخدام المباشر من قبل المستهلكين، وتهدف إلى دعم العلاقة بين أخصائي الرعاية الصحية والمريض، لا استبدالها.

جميع أسماء المنتجات والعلامات التجارية والأسماء التجارية مملوكة لأصحابها، ولا يعني استخدامها أي انتماء أو تأييد. لا تتحمل شركة سيدمكس إينوفيا أي مسؤولية عن أي تبعات ناتجة عن استخدام المعلومات الواردة في هذا الموقع الإلكتروني.

bottom of page